Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

NovoPen ®, the first insulin pen injector ... of NovoPen ® devices (NovoPen ® [1], NovoPen ® 2, NovoPen ® 1.5 and NovoPen ® 3) in the diabetes/insulin therapy area that contained evidence ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...

This human insulin analogue that comes in disposable pens prefilled with 1, 1.5, or 3 mL, dosed in 10-unit increments1 binds reversibly to albumin, which extends its half-life to around 7 days. Steady ...

This increases the risk of developing prediabetes and, potentially, type 2 diabetes. This article looks at the current understanding of insulin resistance and its role as a risk factor for ...